{"commentary":{"count":41,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":41},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07085728\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT07085728","nct_id":"NCT07085728","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07085728. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Cyclophosphamide-Bortezomib-Dexamethasone (4 cycles)","label":"ARM A (Cy-Bor-Dex)","type":"ACTIVE_COMPARATOR"},{"description":"Daratumumab-Bortezomib-Dexamethasone","label":"ARM B (Dara-Bor-Dex)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2038-09-11","type":"ESTIMATED"},"conditions":["Myeloma Multiple"],"enrollment":{"count":74,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cyclophosphamide","type":"DRUG"},{"name":"Bortezomib (VELCADE)","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Daratumumab-hyaluronidase","type":"DRUG"}],"last_update":"2026-09-14","lead_sponsor":"Eastern Cooperative Oncology Group","official_title":"A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone Versus Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma With Light Chain Cast Nephropathy (LCCN)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-01-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Renal Response Rate","timeFrame":"Assessed every cycle on treatment up to 4 cycles (cycle duration=28 days)"}],"references":[],"start_date":{"date":"2026-03-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","url":"https://clinicaltrials.gov/study/NCT07085728"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07085728"}